Skip to content
Sunday, November 22, 2026
Latest
Market United States

Altria’s $12 million vape line shrinks beside $4.76 billion smokeables

Altria's third-quarter 2026 results put its cigarettes-and-smokeables core at 88% of excise-adjusted revenue while vapes and other next-generation goods brought in $12 million, underlining how little the US tobacco major now depends on vaping.

E-Cigarette vs. Analog Cigarette (25221383209)
E-Cigarette vs. Analog Cigarette (25221383209). Photographed 2016-03-06. File photo: Lindsay Fox from Newport beach, United States / Wikimedia Commons, CC BY 2.0. Image: Lindsay Fox from Newport beach, United States Image source · CC BY 2.0 · Display crop and size variants; source image content retained.

Key points

  • Altria's third-quarter 2026 revenue net of excise taxes was $5.44 billion, up 3.6%, with smokeable products at $4.76 billion or 88%.
  • The "all other" category, which covers vaping goods, brought in $12 million in the quarter.
  • Smokeable shipment volume fell 2.9% while on! and on! PLUS pouch shipment volume rose 13%.
  • Altria raised 2026 adjusted earnings guidance to $5.66–$5.74 per share and added $1 billion to its buyback programme, now running to 31 December 2027.
On this page
  1. Smokeables still carry 88% of excise-adjusted revenue
  2. Vaping sits in a $12 million residual while pouches grow 13%
  3. Guidance rises to $5.66–$5.74 per share and buybacks expand
  4. What the mix means for vape suppliers
  5. Retailers see little near-term change in the vape aisle
  6. Questions readers ask

Altria’s non-smokeable and next-generation goods, including vaping products, generated $12 million in its third quarter, against $4.76 billion from smokeables, according to figures the company reported and The Motley Fool analysed.

The same quarter showed excise-adjusted revenue up 3.6% to $5.44 billion while smokeable shipment volume fell 2.9%, a split that matters to anyone selling into the US nicotine market.

Smokeables still carry 88% of excise-adjusted revenue

Smokeable products, led by Marlboro, produced $4.76 billion of the $5.44 billion total, or 88%, the article states. Oral tobacco contributed $667 million, almost all of the remainder.

Reported net revenue rose 1% year over year to $6.13 billion, before the excise-tax adjustment. Adjusted profit increased 4% to $2.55 billion, a net margin of 47%.

Third-quarter 2026 item Amount Change
Reported net revenue $6.13 billion +1% year over year
Revenue net of excise taxes $5.44 billion +3.6%
Smokeable products revenue $4.76 billion 88% of excise-adjusted total
Oral tobacco revenue $667 million Marginal growth
“All other” category, including vapes $12 million Not stated
Smokeable shipment volume Not stated −2.9%
Adjusted profit $2.55 billion +4%
on! and on! PLUS pouch shipment volume Not stated +13%

Vaping sits in a $12 million residual while pouches grow 13%

Altria’s in-house vape development failed and its stakes in vape manufacturers, most visibly Juul Labs, did not deliver, according to the article. Vaping sales now sit inside an “all other” line worth $12 million for the quarter.

Oral nicotine pouches are the growth item instead. Combined shipment volume for on! and on! PLUS rose 13% in the quarter, though oral revenue as a whole grew only marginally.

Guidance rises to $5.66–$5.74 per share and buybacks expand

Altria raised its full-year 2026 adjusted earnings guidance by 4.5% to 6% over 2025, to $5.66–$5.74 per share, the article reports.

Its board authorised a $1 billion increase to the existing share repurchase programme, which had $265 million left, and pushed the deadline to 31 December 2027. Third-quarter free cash flow was close to $3 billion, against under $1.8 billion needed for the dividend and $400 million for buybacks.

Dividend payments currently run at a 5.6% yield.

What the mix means for vape suppliers

The figures show Altria competing for US nicotine spend mainly through cigarettes and pouches, not through vaping. For manufacturers and exporters selling into the US, that leaves vape distribution largely in the hands of independent brands and specialist distributors rather than a large tobacco incumbent. VapeBrief’s analysis is that Altria’s pouch volume growth, rather than its vape line, is the nearer competitive pressure for companies building oral nicotine portfolios.

Retailers see little near-term change in the vape aisle

The results give no sign of an Altria re-entry into vaping at scale in the current plan. Retailers and distributors that stock Altria lines face the same mix of declining smokeable volume and rising prices, with pouches the only category the company flagged as growing.

The next dated checkpoint is the company’s reporting of full-year 2026 results against the raised guidance of $5.66–$5.74 per share.

Questions readers ask

How much revenue does Altria make from vaping?

Altria does not break vaping out separately. Its "all other" category, which covers next-generation goods including vape sales, generated $12 million in the third quarter of 2026, against $4.76 billion from smokeable products.

What did Altria change in its 2026 guidance?

Altria raised full-year 2026 adjusted earnings guidance to $5.66–$5.74 per share, a rise of 4.5% to 6% over 2025, and expanded its share repurchase programme by $1 billion with a deadline of 31 December 2027.

Share

Sources

18+ only. This site is for adult readers and provides news and information only. It is not medical, legal or purchase advice. Nicotine is addictive. Always check the official text of any regulation in your market. Health Information

VapeBrief Markets Desk

A shared VapeBrief publication label for market, industry and trade-event coverage, not a named person or a claim about team size or professional qualifications.

About this byline →

Daily Brief newsletter

A concise email at 08:00 U.S. Eastern time each day, with links to the previous day’s published briefs.

Topics of interest

Active immediately, no confirmation click needed. Every email includes an unsubscribe link. See our Privacy Policy.